GUOFANG CAPITAL
Guofang Capital was initiated by Shanghai International Group in 2017. Guofang Capital is a professional market-based equity investment platform with an asset under management (AUM) of over 10 billion RMB. Focused on healthcare, AI and IoT industries, the Yangtze River Delta Synergy Industry Investment Fund managed by Guofang Capital aims to play a leading role in guiding private capitals, establishing industrial investment fund ecosystem, and promoting the overall development of China's strategic industries through fund-of-fund (FOF) and direct investment.
GUOFANG CAPITAL
Status:
Active
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-07-25 | Hengyu Biotechnology | Guofang Capital investment in Series A - Hengyu Biotechnology | N/A |
| 2021-12-27 | Zhuishi Technology | Guofang Capital investment in Series A - Zhuishi Technology | 100 M CNY |
| 2021-12-27 | Trensor | Guofang Capital investment in Series B - Trensor | 15.69 M USD |
| 2021-11-01 | Paraview Software | Guofang Capital investment in Series D - Paraview Software | N/A |
| 2021-10-14 | Danwang Medical | Guofang Capital investment in Series A - Danwang Medical | 120 M CNY |
| 2021-02-09 | Neurophth Therapeutics | Guofang Capital investment in Series B - Neurophth Therapeutics | 61.9 M USD |